Human iPS cell-based therapy: Considerations before clinical applications

 Abstract

Generation of induced pluripotent stem (iPS) cells has revolutionized the field of regenerative medicine. With the exponential increase in iPS cell research in the past three years, human iPS cells have been derived with different technologies and from various cell types. From a translational perspective, however, a number of issues must be addressed before safe and high quality patient-specific iPS cells can be derived for clinical applications. In addition, iPS cell-based therapies also need to be thoroughly evaluated in pre-clinical animal models before they can be applied to human subjects.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
880 - 885
doi
10.4161/cc.9.5.10827
Type
Review
 Metrics
 Cite This Article
 Permissions
 Permissions
 Reprints
Human iPS cell-based therapy: Considerations before clinical applications